Use of Magnesium Sulphate in Persistent Pulmonary Hypertension of Newborn

M A A Mamun¹, S Begum², M Hussain³, A Jabbar⁴

Abstract

**Background**: One of the common causes of respiratory distress in neonate is persistent pulmonary hypertension of newborn (PPHN) and has been estimated to occur in 2 per 1000 live born term infants.

**Objective**: To evaluate the effect of injectable Magnesium Sulphate (MgSO₄) in the treatment of Persistent Pulmonary Hypertension of Newborn.

**Methodology**: It was a prospective, nonrandomized, clinical study conducted from August 2015 to July 2017 among 25 neonates having moderate to severe PPHN in the Pediatric Cardiac Intensive Care Unit (CICU) of Dhaka Shishu (Children) Hospital. Injectable Magnesium Sulphate was used along with other supportive management. Outcome measures include drop of pulmonary vascular resistance and increase oxygenation. Side effects of Magnesium Sulphate were observed and outcome was recorded. Data were analyzed by using SPSS version 17.

**Results**: There was significant improvement of oxygenation and decrease in pulmonary vascular resistance at 72 hours after use of MgSO₄ (p=0.000). Complications were present in 28% cases which include hypotension in 16% patients, urinary retention in 8% and altered GI function in 8% cases. Mortality was 16% among study population.

**Conclusion**: MgSO₄ is effective in improving oxygenation and reduction of pulmonary vascular resistance in PPHN.

**Key Wards**: Magnesium Sulphate, PPHN, neonate.

DOI: https://doi.org/10.3329/nimcj.v10i2.45430

Northern International Medical College Journal Vol. 10 No. 2 January 2019, Page 370-372
Use of Magnesium Sulphate in Persistent Pulmonary Hypertension of Newborn

M A A Mamun et al.

January 2019 Volume 10 Number 2

expertise required for these expensive therapies.7

Magnesium sulphate is a natural Ca channel blocker that antagonizes Ca ion entry into smooth muscle cell thus promoting vasodilatation. It is safe and cheaper alternative for first line treatment in moderate PPHN.8,9 A recent study concluded that where Nitric Oxide facilities are not available, Magnesium Sulphate (MgSO4) is a cheap alternative for first line treatment of moderate PPHN.10 Very few data are available in our country regarding outcome and treatment of PPHN in Bangladesh. Therefore, this study was conducted to find out the effectiveness of Magnesium Sulphate in PPHN.

Materials and Methods

It was an prospective, nonrandomized, clinical study, conducted from August 2015 to July 2017 in the Cardiac Intensive Care Unit (CICU) of Dhaka Shishu (Children) Hospital. During this period neonates having respiratory distress and/or cyanosis were screened and with pre and post ductal O2 saturation difference>10% were undergone echocardiography. Moderate to severe PPHN were identified among 25 neonates and were treated with Magnesium Sulphate with a loading dose of 100mg/kg over 30 min followed by 20-50 mg/kg/h for 5 hours for 3 days. No other vasodilator drug was administered before or during the treatment. Pre- ductal and post ductal peripheral capillary oxygen saturation (SpO2) was monitored. Outcome measures include drop of pulmonary vascular resistance measured by right ventricular systolic pressure, increased partial pressure of oxygen in arterial blood (PaO2), mechanical ventilator duration and time interval to improve, measured by drop of Right ventricular systolic pressure (RVSP)<25 mmHg and increase PaO2>30 mmHg. Side effect was observed in the patient and outcome was recorded. Consent from the parents and permission from Ethical Review Committee of Dhaka Shishu (Children) Hospital was taken. Data were analyzed by using SPSS version 17.

Result

Mean age of study neonates were 32.12±14.26 hours. There was significant improvement of oxygenation from diagnosis to 72 hour after treatment (p=0.000) [Table I].

Paired samples t test was done to assess the comparison. Statistically significant improvement was found at 72th hour regarding drop of right ventricular systolic pressure (RVSP) [Table II].

Complications were present in 28% cases. Hypotension developed in 4 patients, urinary retention develops 2 patients and altered GI function was found in 2 patients (Table-III).

Mean time was taken to improve was 86.66±34.98 hours, mean hospital stay was 9.48±3.39 days and 16% cases died (Table-IV).

Discussion

In this study we found that pulmonary vascular resistance (measured by echocardiographic evaluation)dropped remarkably by MgSO4. Shaltouta et al10 also found significant drop in pulmonary vascular resistance in their study.

In this study improvement of oxygenation measured by changes in partial pressure of oxygenation and ventilator duration. A
significant improvement of patients’ oxygenation parameters were noted at 72 hours which was comparable with other studies.\textsuperscript{10-12} Ulsa et al\textsuperscript{13} in a recent randomized clinical trial also showed that MgSO\textsubscript{4} was effective in the improvement of oxygenation in PPHN. Marked improvement in partial pressure oxygen at 6 hours and maximum improvement at 24 hours were found by Chandran et al\textsuperscript{11}. In this study oxygenation was started to improve at 6 hours but significantly improved after 12 hours. Mean ventilatory time support was 112.10±20.48 hours which was comparable with Tolsa et al\textsuperscript{12}. Chandran et al\textsuperscript{11} found in 2 patients. Chandran et al\textsuperscript{11} found that feeding was well tolerated in their study. However, other side effects of MgSO\textsubscript{4} were noted by Tolsa et al\textsuperscript{12} and Daffa et al\textsuperscript{14} also concluded that MgSO\textsubscript{4} may be considered as an alternative treatment in PPHN when no other modalities are available.

At high serum concentrations, magnesium is a muscle relaxant, a sedative, and a potent vasodilatory drug. Blood pressure was monitored and hypotension was observed in 4 of our patients (16\%). In response to hypotension MgSO\textsubscript{4} infusion was temporarily discontinued and saline infusion was given. Shaltouta et al\textsuperscript{10} reported 20\% hypotension in their study in case of MgSO\textsubscript{4}. No systemic hypotension were noted by Tolsa et al\textsuperscript{12}, Chandran et al\textsuperscript{11} in their study maintained mean blood pressure with short periods of dopamine alone or in combination with dobutamine. Dopamine was commenced at 5-10 µg/kg/min before the loading dose of MgSO\textsubscript{4} to prevent systemic hypotension. The slight decrease in heart rate was also found and easily corrected by dobutamine support.

No patient experienced decrease heart rate in our study. Urinary retention develops in 2 patients and altered GI function was found in 2 patients. Chandran et al\textsuperscript{11} found that feeding was well tolerated in their study. However, other side effects of MgSO\textsubscript{4} (flaccidity and hypocalcaemia) were not found in the present study.

Despite a better understanding of the underlying pathophysiology and the various treatments that have been proposed, pulmonary hypertension remains a potentially fatal complication among newborns. In this study mortality was 16\%.

In the study done by Chandran et al it was found that all infants who were survived had normal neurological findings at discharge from the hospital.\textsuperscript{11} The neurodevelopmental assessment was normal at 6 and 12 months of age in the study done by Tolsa et al.\textsuperscript{12} In our study Neurodevelopmental assessment was also found normal in all infants at discharge.

**Conclusion**

Magnesium Sulphate is effective in improving oxygenation and reduction of pulmonary vascular resistance in PPHN.

**Acknowledgement**

This study was funded by Ministry of Science and Technology, Government of People’s Republic of Bangladesh.

**References**